Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, Elizabeth Macintyre, MD, PhD, of the Hôpital Necker-Enfants Malades, Paris, France, explains why she believes typical B-cell lineage acute lymphoblastic leukemia (ALL) and T-cell ALL should be characterized as different diseases.
The ALL frontier: should T-ALL be classed as a different disease?
